Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

NeurAxis offers FDA-cleared IB-Stim device for pediatric IBS pain. Despite positive advancements, market recognition lags.

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025 ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...